NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025)

NewAmsterdam Pharma (NAMS) reported Other Operating Expenses of -$1000.0 for Q3 2025.

NewAmsterdam Pharma (NAMS) Other Operating Expenses (2025) Analysis & Trends

NewAmsterdam Pharma (NAMS) has 1 years of Other Operating Expenses data on file, last reported at -$1000.0 in Q3 2025.

For the quarter ending Q3 2025, Other Operating Expenses changed N/A year-over-year to -$1000.0; the trailing twelve-month figure through Mar 2026 stood at -$1000.0 (changed N/A YoY), and the FY2022 full-year result was $61.8 million, changed N/A from the prior year.
Other Operating Expenses held at -$1000.0 in Q3 2025.
In the past five years, Other Operating Expenses ranged from a high of -$1000.0 in Q3 2025 to a low of -$1000.0 in Q3 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn
7	Belite Bio	61.40 Bn	61.40 Bn	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-
10	NewAmsterdam Pharma	3.64 Bn	3.64 Bn	-

Historic Data

Download Data

Date	Value
Sep 30, 2025	-1,000.00